Generate Biomedicines (NASDAQ:GENB) Shares Gap Up – Time to Buy?

Shares of Generate Biomedicines Inc (NASDAQ:GENB) gapped up prior to trading on Wednesday. The stock had previously closed at $12.26, but opened at $12.61. Generate Biomedicines shares last traded at $12.5120, with a volume of 796,486 shares trading hands.

Analysts Set New Price Targets

Several research firms have recently commented on GENB. Weiss Ratings upgraded Generate Biomedicines from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, September 25th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Generate Biomedicines in a report on Monday, October 5th. Finally, Wall Street Zen upgraded shares of Generate Biomedicines from a “sell” rating to a “hold” rating in a research report on Saturday, September 26th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $26.40.

Generate Biomedicines Trading Up 4.3%

The business has a 50 day moving average price of $15.46 and a 200-day moving average price of $14.44. The firm has a market capitalization of $1.68 billion and a PE ratio of -8.21.

Generate Biomedicines (NASDAQ:GENB) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). The company had revenue of $6.31 million during the quarter. On average, equities research analysts forecast that Generate Biomedicines Inc will post -2.29 earnings per share for the current year.

Institutional Investors Weigh In On Generate Biomedicines

A number of hedge funds and other institutional investors have recently bought and sold shares of GENB. State Street Corp purchased a new stake in shares of Generate Biomedicines during the 2nd quarter worth $8,883,000. The Manufacturers Life Insurance Company purchased a new position in shares of Generate Biomedicines in the 2nd quarter valued at about $1,431,000. Squarepoint Ops LLC purchased a new position in shares of Generate Biomedicines in the 2nd quarter valued at about $530,000. AXQ Capital LP purchased a new position in shares of Generate Biomedicines in the 2nd quarter valued at about $218,000. Finally, Braidwell LP acquired a new stake in shares of Generate Biomedicines in the second quarter valued at about $55,398,000.

Generate Biomedicines Company Profile

Generate Biomedicines is a biotechnology company focused on discovering and developing protein-based medicines. The company uses generative artificial intelligence, machine learning and laboratory-based biological research to design new therapeutic proteins and identify candidates with potential applications in a range of diseases.

Its platform, often described as a generative biology approach, is designed to model biological systems and create proteins with desired characteristics rather than relying solely on modifying naturally occurring molecules.